Since biologic events underlie clinical outcomes, we hypothesize that unraveling mechanisms of intracellular signaling and metastasis in lung cancers will lead to the identification of new targets for therapy for these illnesses and for individual patients. Our experience developing EGFR and ALK kinase inhibitors, and the discoveries that mutations in EGFR and KRAS and ALK- rearrangements underlie sensitivity and resistance to targeted therapies, have shown the practicality and potential of this approach. Our 4 research projects and 3 cores propose to continue a decade long iterative research process uniting clinical and laboratory observations. These efforts have linked genetic aberrations in tumors to outcomes in patients and identified agents targeting these same aberrations that benefit persons with lung cancers. This grant embraces investigators, technologies, and pathways, each focused by specific clinical questions, proposing to identify targets for therapies in lung cancers. Project 1 (Massagu) identifies mediators of metastasis and immune evasion that can serve as targets for intervention. Project 2 (Rosen) probes signaling in BRAF- and KRAS-driven lung cancers. Project 3 (Lovely) investigates mechanisms and modulators of sensitivity and resistance to EGFR and ALK kinase inhibitors. Project 4 (Lowe) uses mouse models and RNA interference to interrogate KRAS- driven lung cancers focusing on combinatorial strategies including the allele specific inhibitors studied in Project 2 and probing the impact of therapy-induced senescence on immune surveillance. Our Molecular Profiling and Pathology Core crystallizes more than a decade of experience in precise pathologic characterization, and use of the next-generation technologies for comprehensive molecular profiling of lung cancers. The Biostatistics and Bioinformatics Core ensures consistency in biostatistical analyses and provides projects and the Pathology Core with analytic capabilities for genomic data. The Administrative Core has created an organizational structure that assures integration and interaction by facilitating communication and dissemination of findings and providing a forum for the principal investigators, leaders, and the Executive and Scientific Advisory Committees to conduct scientific review and integration of new opportunities to accelerate progress.

Public Health Relevance

Lung cancers are America?s leading cancer killers, responsible for 158,000 deaths this year. This grant addresses two of the most critical roadblocks to improving the care and curability of persons with these illnesses: understanding how cancers spread (metastasis) and the lack of medicines to prevent metastases or to eradicate cancers that have spread from the lungs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Mo, Qianxing; Shen, Ronglai; Guo, Cui et al. (2018) A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 19:71-86
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Gao, Yijun; Chang, Matthew T; McKay, Daniel et al. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov 8:648-661
Arbour, Kathryn C; Jordan, Emmett; Kim, Hyunjae Ryan et al. (2018) Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24:334-340
Gallant, Jean-Nicolas; Lovly, Christine M (2018) Established, emerging and elusive molecular targets in the treatment of lung cancer. J Pathol 244:565-577
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902

Showing the most recent 10 out of 188 publications